VISTIN PHARMA ASA (VISTN.OL) Stock Fundamental Analysis

OSL:VISTN • NO0010734122

21.3 NOK
+0.6 (+2.9%)
Last: Feb 20, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to VISTN. VISTN was compared to 52 industry peers in the Pharmaceuticals industry. VISTN is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. VISTN has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year VISTN was profitable.
  • VISTN had a positive operating cash flow in the past year.
  • In multiple years VISTN reported negative net income over the last 5 years.
  • In multiple years VISTN reported negative operating cash flow during the last 5 years.
VISTN.OL Yearly Net Income VS EBIT VS OCF VS FCFVISTN.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

  • VISTN's Return On Assets of 18.36% is amongst the best of the industry. VISTN outperforms 96.15% of its industry peers.
  • VISTN has a better Return On Equity (24.96%) than 69.23% of its industry peers.
  • With an excellent Return On Invested Capital value of 20.45%, VISTN belongs to the best of the industry, outperforming 82.69% of the companies in the same industry.
Industry RankSector Rank
ROA 18.36%
ROE 24.96%
ROIC 20.45%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VISTN.OL Yearly ROA, ROE, ROICVISTN.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

  • The Profit Margin of VISTN (17.16%) is better than 69.23% of its industry peers.
  • In the last couple of years the Profit Margin of VISTN has declined.
  • VISTN has a Operating Margin of 20.82%. This is comparable to the rest of the industry: VISTN outperforms 50.00% of its industry peers.
  • In the last couple of years the Operating Margin of VISTN has grown nicely.
  • The Gross Margin of VISTN (66.40%) is worse than 63.46% of its industry peers.
  • VISTN's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 20.82%
PM (TTM) 17.16%
GM 66.4%
OM growth 3Y18.14%
OM growth 5Y21.91%
PM growth 3Y17.49%
PM growth 5Y-12.88%
GM growth 3Y-0.06%
GM growth 5Y7.35%
VISTN.OL Yearly Profit, Operating, Gross MarginsVISTN.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • VISTN has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • VISTN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VISTN.OL Yearly Shares OutstandingVISTN.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
VISTN.OL Yearly Total Debt VS Total AssetsVISTN.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

  • VISTN has an Altman-Z score of 7.65. This indicates that VISTN is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of VISTN (7.65) is better than 92.31% of its industry peers.
  • The Debt to FCF ratio of VISTN is 0.32, which is an excellent value as it means it would take VISTN, only 0.32 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 0.32, VISTN belongs to the top of the industry, outperforming 98.08% of the companies in the same industry.
  • A Debt/Equity ratio of 0.07 indicates that VISTN is not too dependend on debt financing.
  • VISTN has a Debt to Equity ratio of 0.07. This is amongst the best in the industry. VISTN outperforms 84.62% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF 0.32
Altman-Z 7.65
ROIC/WACC2.4
WACC8.52%
VISTN.OL Yearly LT Debt VS Equity VS FCFVISTN.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • VISTN has a Current Ratio of 2.23. This indicates that VISTN is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.23, VISTN is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
  • A Quick Ratio of 1.16 indicates that VISTN should not have too much problems paying its short term obligations.
  • The Quick ratio of VISTN (1.16) is better than 65.38% of its industry peers.
Industry RankSector Rank
Current Ratio 2.23
Quick Ratio 1.16
VISTN.OL Yearly Current Assets VS Current LiabilitesVISTN.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 27.20% over the past year.
  • Measured over the past years, VISTN shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.03% on average per year.
  • The Revenue has been growing slightly by 7.38% in the past year.
  • Measured over the past years, VISTN shows a quite strong growth in Revenue. The Revenue has been growing by 13.56% on average per year.
EPS 1Y (TTM)27.2%
EPS 3Y36.14%
EPS 5Y-1.03%
EPS Q2Q%11.83%
Revenue 1Y (TTM)7.38%
Revenue growth 3Y15.87%
Revenue growth 5Y13.56%
Sales Q2Q%2.84%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VISTN.OL Yearly Revenue VS EstimatesVISTN.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
VISTN.OL Yearly EPS VS EstimatesVISTN.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 12.10 indicates a correct valuation of VISTN.
  • 80.77% of the companies in the same industry are more expensive than VISTN, based on the Price/Earnings ratio.
  • VISTN is valuated cheaply when we compare the Price/Earnings ratio to 26.99, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 12.1
Fwd PE N/A
VISTN.OL Price Earnings VS Forward Price EarningsVISTN.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of VISTN indicates a rather cheap valuation: VISTN is cheaper than 80.77% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, VISTN is valued cheaper than 80.77% of the companies in the same industry.
Industry RankSector Rank
P/FCF 14.55
EV/EBITDA 7.87
VISTN.OL Per share dataVISTN.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 6.04%, VISTN is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 1.91, VISTN pays a better dividend. On top of this VISTN pays more dividend than 96.15% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.85, VISTN pays a better dividend.
Industry RankSector Rank
Dividend Yield 6.04%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • VISTN pays out 99.41% of its income as dividend. This is not a sustainable payout ratio.
DP99.41%
EPS Next 2YN/A
EPS Next 3YN/A
VISTN.OL Yearly Income VS Free CF VS DividendVISTN.OL Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M -150M
VISTN.OL Dividend Payout.VISTN.OL Dividend Payout, showing the Payout Ratio.VISTN.OL Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

VISTIN PHARMA ASA

OSL:VISTN (2/20/2026, 7:00:00 PM)

21.3

+0.6 (+2.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-12
Earnings (Next)04-24
Inst Owners14.3%
Inst Owner ChangeN/A
Ins Owners4.89%
Ins Owner ChangeN/A
Market Cap944.44M
Revenue(TTM)454.83M
Net Income(TTM)78.06M
Analysts40
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 6.04%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP99.41%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 12.1
Fwd PE N/A
P/S 2.08
P/FCF 14.55
P/OCF 11.85
P/B 3.02
P/tB 3.02
EV/EBITDA 7.87
EPS(TTM)1.76
EY8.26%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)1.46
FCFY6.87%
OCF(TTM)1.8
OCFY8.44%
SpS10.26
BVpS7.05
TBVpS7.05
PEG (NY)N/A
PEG (5Y)N/A
Graham Number16.71
Profitability
Industry RankSector Rank
ROA 18.36%
ROE 24.96%
ROCE 27.85%
ROIC 20.45%
ROICexc 20.64%
ROICexgc 20.64%
OM 20.82%
PM (TTM) 17.16%
GM 66.4%
FCFM 14.27%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y18.14%
OM growth 5Y21.91%
PM growth 3Y17.49%
PM growth 5Y-12.88%
GM growth 3Y-0.06%
GM growth 5Y7.35%
F-Score7
Asset Turnover1.07
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF 0.32
Debt/EBITDA 0.18
Cap/Depr 68.54%
Cap/Sales 3.25%
Interest Coverage 250
Cash Conversion 68.54%
Profit Quality 83.14%
Current Ratio 2.23
Quick Ratio 1.16
Altman-Z 7.65
F-Score7
WACC8.52%
ROIC/WACC2.4
Cap/Depr(3y)280.38%
Cap/Depr(5y)338.81%
Cap/Sales(3y)11.99%
Cap/Sales(5y)13.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.2%
EPS 3Y36.14%
EPS 5Y-1.03%
EPS Q2Q%11.83%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.38%
Revenue growth 3Y15.87%
Revenue growth 5Y13.56%
Sales Q2Q%2.84%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.53%
EBIT growth 3Y36.89%
EBIT growth 5Y38.44%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y64.99%
FCF growth 3YN/A
FCF growth 5Y158.58%
OCF growth 1Y3.04%
OCF growth 3Y99.03%
OCF growth 5Y41.62%

VISTIN PHARMA ASA / VISTN.OL FAQ

What is the fundamental rating for VISTN stock?

ChartMill assigns a fundamental rating of 5 / 10 to VISTN.OL.


What is the valuation status for VISTN stock?

ChartMill assigns a valuation rating of 4 / 10 to VISTIN PHARMA ASA (VISTN.OL). This can be considered as Fairly Valued.


Can you provide the profitability details for VISTIN PHARMA ASA?

VISTIN PHARMA ASA (VISTN.OL) has a profitability rating of 5 / 10.


What is the financial health of VISTIN PHARMA ASA (VISTN.OL) stock?

The financial health rating of VISTIN PHARMA ASA (VISTN.OL) is 8 / 10.


Can you provide the dividend sustainability for VISTN stock?

The dividend rating of VISTIN PHARMA ASA (VISTN.OL) is 5 / 10 and the dividend payout ratio is 99.41%.